Highest Price Target1
Lowest Price Target1
Consensus Price Target1
Analyst Rating Summary1
Analyst Firms Making Recommendations1
- Goldman Sachs
- Credit Suisse
- Cowen & Co.
- BMO Capital
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for AbCellera Biologics
What is the target price for AbCellera Biologics (ABCL)?
The latest price target for AbCellera Biologics (NASDAQ: ABCL) was reported by Benchmark on August 31, 2023. The analyst firm set a price target for $12.00 expecting ABCL to rise to within 12 months (a possible 141.21% upside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for AbCellera Biologics (ABCL)?
The latest analyst rating for AbCellera Biologics (NASDAQ: ABCL) was provided by Benchmark, and AbCellera Biologics maintained their buy rating.
When is the next analyst rating going to be posted or updated for AbCellera Biologics (ABCL)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AbCellera Biologics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AbCellera Biologics was filed on August 31, 2023 so you should expect the next rating to be made available sometime around August 31, 2024.
Is the Analyst Rating AbCellera Biologics (ABCL) correct?
While ratings are subjective and will change, the latest AbCellera Biologics (ABCL) rating was a maintained with a price target of $20.00 to $12.00. The current price AbCellera Biologics (ABCL) is trading at is $4.97, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.